PriceTargets.com logo

Revvity - PKI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 05/16/2023 12:59 AM ET
+0 (0.00%)
Get New Revvity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PKI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PKI

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Revvity in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for PKI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Revvity. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$53.00 ➝ $54.00
11/15/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$52.00 ➝ $54.00
11/2/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$48.00 ➝ $53.00
5/15/2023CitigroupLower Target$170.00 ➝ $160.00
5/12/2023Stifel NicolausLower Target$145.00 ➝ $135.00
5/12/2023Robert W. BairdLower Target$182.00 ➝ $165.00
5/12/2023BarclaysLower Target$140.00 ➝ $125.00
2/15/2023Credit Suisse GroupReiterated RatingNeutral$160.00
2/15/2023Robert W. BairdLower TargetOutperform$185.00 ➝ $182.00
1/24/2023BarclaysLower TargetEqual Weight$145.00 ➝ $140.00
12/12/2022CitigroupUpgradeNeutral ➝ Buy$135.00 ➝ $170.00
12/6/2022CowenUpgradeMarket Perform ➝ Outperform$164.00
12/6/2022CowenUpgradeMarket Perform ➝ Outperform$192.00 ➝ $164.00
11/28/2022BarclaysUpgradeUnderweight ➝ Equal Weight$130.00 ➝ $145.00
11/14/2022Credit Suisse GroupLower TargetNeutral$175.00 ➝ $160.00
11/9/2022Robert W. BairdLower Target$202.00 ➝ $178.00
10/6/2022BarclaysLower TargetUnderweight$140.00 ➝ $120.00
9/12/2022BarclaysLower TargetUnderweight$149.00 ➝ $140.00
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$175.00
8/18/2022Stifel NicolausDowngradeBuy ➝ Hold$190.00 ➝ $170.00
8/2/2022BarclaysBoost TargetUnderweight$125.00 ➝ $149.00
8/2/2022Robert W. BairdBoost TargetOutperform$198.00 ➝ $202.00
8/2/2022Bank of AmericaDowngradeBuy ➝ Neutral$178.00
7/20/2022UBS GroupInitiated CoverageBuy$160.00
7/14/2022The Goldman Sachs GroupLower TargetNeutral$200.00 ➝ $175.00
5/17/2022BarclaysInitiated CoverageUnderweight$125.00
5/4/2022Robert W. BairdLower Target$216.00 ➝ $198.00
5/4/2022CitigroupLower Target$185.00 ➝ $170.00
12/16/2021The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$200.00
12/14/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$200.00 ➝ $205.00
11/17/2021Royal Bank of CanadaBoost TargetOutperform$49.00 ➝ $50.00
11/3/2021Wells Fargo & CompanyBoost TargetOverweight$190.00 ➝ $200.00
11/3/2021Robert W. BairdBoost TargetHold ➝ Outperform$183.00 ➝ $206.00
8/9/2021Royal Bank of CanadaBoost TargetOutperform$48.00 ➝ $49.00
7/27/2021Evercore ISIReiterated RatingOutperform$174.00 ➝ $170.86
7/27/2021Robert W. BairdReiterated RatingOutperform$150.00 ➝ $172.11
6/15/2021Wolfe ResearchUpgradeMarket Perform ➝ Outperform
2/3/2021CitigroupBoost Target$150.00 ➝ $155.00
1/7/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$140.00 ➝ $175.00
12/11/2020Smith Barney CitigroupBoost Target$140.00 ➝ $150.00
12/2/2020The Goldman Sachs GroupInitiated CoverageBuy$160.00
11/12/2020The Goldman Sachs GroupInitiated CoverageBuy$50.00
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$150.00
11/9/2020Needham & Company LLCBoost TargetBuy$139.00 ➝ $193.00
10/29/2020Smith Barney CitigroupBoost Target$120.00 ➝ $140.00
10/29/2020Wells Fargo & CompanyBoost TargetEqual Weight$130.00 ➝ $140.00
10/29/2020Robert W. BairdBoost TargetOutperform$137.00 ➝ $151.00
9/11/2020Needham & Company LLCUpgradeHold ➝ Buy$139.00
8/10/2020BMO Capital MarketsBoost TargetOutperform$44.00 ➝ $45.00
7/29/2020JPMorgan Chase & Co.Boost TargetNeutral$85.00 ➝ $105.00
7/29/2020Stifel NicolausBoost TargetBuy$95.00 ➝ $125.00
7/29/2020Wells Fargo & CompanyBoost TargetEqual Weight$105.00 ➝ $130.00
7/29/2020CfraUpgradeHold ➝ Buy
7/13/2020Needham & Company LLCInitiated CoverageHold
5/7/2020UBS GroupBoost TargetNeutral$95.00 ➝ $96.00
5/6/2020Robert W. BairdBoost TargetOutperform$94.00 ➝ $99.00
5/6/2020CfraLower TargetHold$100.00 ➝ $94.00
5/6/2020JPMorgan Chase & Co.Boost TargetNeutral$80.00 ➝ $85.00
4/28/2020UBS GroupLower TargetNeutral$100.00 ➝ $95.00
4/20/2020CitigroupBoost TargetNeutral$70.00 ➝ $85.00
4/2/2020JPMorgan Chase & Co.Lower TargetOverweight$49.00 ➝ $45.00
4/2/2020Stifel NicolausLower TargetBuy$102.00 ➝ $80.00
3/30/2020Wells Fargo & CompanyLower TargetEqual Weight$100.00 ➝ $80.00
3/26/2020BarclaysLower TargetEqual Weight$100.00 ➝ $94.00
3/20/2020CitigroupLower TargetNeutral$100.00 ➝ $70.00
1/28/2020UBS GroupBoost TargetNeutral$92.00 ➝ $100.00
1/14/2020TD SecuritiesBoost TargetBuy$54.00 ➝ $56.00
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$105.00
1/6/2020CitigroupInitiated CoverageNeutral$100.00
1/3/2020Needham & Company LLCInitiated CoverageHold$79.00
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$89.00 ➝ $114.00
11/21/2019Stifel NicolausReiterated RatingBuy
(Data available from 11/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Revvity logo
Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $127.73
Low: $115.24
High: $137.11

52 Week Range

Now: N/A

Volume

1,633,000 shs

Average Volume

851,117 shs

Market Capitalization

$14.57 billion

P/E Ratio

15.01

Dividend Yield

0.24%

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Revvity?

The following Wall Street analysts have issued stock ratings on Revvity in the last twelve months: StockNews.com.
View the latest analyst ratings for PKI.

What is the current price target for Revvity?

0 Wall Street analysts have set twelve-month price targets for Revvity in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Revvity in the next year.
View the latest price targets for PKI.

What is the current consensus analyst rating for Revvity?

Revvity currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PKI.

What other companies compete with Revvity?

Other companies that are similar to Revvity include Agilent Technologies, Mettler-Toledo International, Illumina, Waters and Bio-Techne. Learn More about companies similar to Revvity.

How do I contact Revvity's investor relations team?

Revvity's physical mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company's listed phone number is (781) 663-6900 and its investor relations email address is [email protected]. The official website for Revvity is www.perkinelmer.com. Learn More about contacing Revvity investor relations.